Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Increased stress associated with head-out plethysmography testing can exacerbate respiratory effects and lead to mortality in rats.

Lynch JJ 3rd, Rossignol E, Moehrle JJ, Van Vleet TR, Marsh KC, Parman T, Mirsalis J, Ottinger SE, Segreti JA, Rao M, Mittelstadt SW.

J Pharmacol Toxicol Methods. 2019 May 11:106580. doi: 10.1016/j.vascn.2019.106580. [Epub ahead of print]

PMID:
31085318
2.

In Vitro and In Vivo Activity of Amiodarone Against Ebola Virus.

Dyall J, Johnson JC, Hart BJ, Postnikova E, Cong Y, Zhou H, Gerhardt DM, Michelotti J, Honko AN, Kern S, DeWald LE, O'Loughlin KG, Green CE, Mirsalis JC, Bennett RS, Olinger GG Jr, Jahrling PB, Hensley LE.

J Infect Dis. 2018 Nov 22;218(suppl_5):S592-S596. doi: 10.1093/infdis/jiy345.

PMID:
30016444
3.

Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.

Curreli F, Belov DS, Kwon YD, Ramesh R, Furimsky AM, O'Loughlin K, Byrge PC, Iyer LV, Mirsalis JC, Kurkin AV, Altieri A, Debnath AK.

Eur J Med Chem. 2018 Jun 25;154:367-391. doi: 10.1016/j.ejmech.2018.04.062. Epub 2018 May 12.

4.

Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection.

Ekins S, Lingerfelt MA, Comer JE, Freiberg AN, Mirsalis JC, O'Loughlin K, Harutyunyan A, McFarlane C, Green CE, Madrid PB.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01711-17. doi: 10.1128/AAC.01711-17. Print 2018 Feb.

5.

Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus.

Cong Y, Dyall J, Hart BJ, DeWald LE, Johnson JC, Postnikova E, Zhou H, Gross R, Rojas O, Alexander I, Josleyn N, Zhang T, Michelotti J, Janosko K, Glass PJ, Flint M, McMullan LK, Spiropoulou CF, Mierzwa T, Guha R, Shinn P, Michael S, Klumpp-Thomas C, McKnight C, Thomas C, Eakin AE, O'Loughlin KG, Green CE, Catz P, Mirsalis JC, Honko AN, Olinger GG Jr, Bennett RS, Holbrook MR, Hensley LE, Jahrling PB.

PLoS One. 2016 Nov 30;11(11):e0166318. doi: 10.1371/journal.pone.0166318. eCollection 2016.

6.

Evaluation of Cardiac Toxicity Biomarkers in Rats from Different Laboratories.

Kim K, Chini N, Fairchild DG, Engle SK, Reagan WJ, Summers SD, Mirsalis JC; Cardiac Hypertrophy Working Group of the Predictive Safety Testing Consortium.

Toxicol Pathol. 2016 Dec;44(8):1072-1083. doi: 10.1177/0192623316668276. Epub 2016 Sep 28.

7.

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.

Brown AN, Drusano GL, Adams JR, Rodriquez JL, Jambunathan K, Baluya DL, Brown DL, Kwara A, Mirsalis JC, Hafner R, Louie A.

MBio. 2015 Nov 3;6(6):e01741-15. doi: 10.1128/mBio.01741-15.

8.

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.

Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, Njoroge JW, El Mazouni F, Lao Y, Kokkonda S, Tomchick DR, Deng X, Laird T, Bhatia SN, March S, Ng CL, Fidock DA, Wittlin S, Lafuente-Monasterio M, Benito FJ, Alonso LM, Martinez MS, Jimenez-Diaz MB, Bazaga SF, Angulo-Barturen I, Haselden JN, Louttit J, Cui Y, Sridhar A, Zeeman AM, Kocken C, Sauerwein R, Dechering K, Avery VM, Duffy S, Delves M, Sinden R, Ruecker A, Wickham KS, Rochford R, Gahagen J, Iyer L, Riccio E, Mirsalis J, Bathhurst I, Rueckle T, Ding X, Campo B, Leroy D, Rogers MJ, Rathod PK, Burrows JN, Charman SA.

Sci Transl Med. 2015 Jul 15;7(296):296ra111. doi: 10.1126/scitranslmed.aaa6645.

9.

Preclinical studies on the pharmacokinetics, safety, and toxicology of oxfendazole: toward first in human studies.

Codd EE, Ng HH, McFarlane C, Riccio ES, Doppalapudi R, Mirsalis JC, Horton RJ, Gonzalez AE, Garcia HH, Gilman RH; Cysticercosis Working Group in Peru.

Int J Toxicol. 2015 Mar-Apr;34(2):129-37. doi: 10.1177/1091581815569582. Epub 2015 Feb 20.

10.

Tenofovir disoproxil fumarate: toxicity, toxicokinetics, and toxicogenomics analysis after 13 weeks of oral administration in mice.

Ng HH, Stock H, Rausch L, Bunin D, Wang A, Brill S, Gow J, Mirsalis JC.

Int J Toxicol. 2015 Jan-Feb;34(1):4-10. doi: 10.1177/1091581814565669. Epub 2015 Jan 7.

11.

(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.

Jiménez-Díaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, Endsley AN, Fedewa G, Guiguemde WA, Gómez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC, Matheny A, Martínez MS, Miller G, Rodríguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD, Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock DA, Gamo FJ, Charman SA, Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM, Guy RK.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5455-62. doi: 10.1073/pnas.1414221111. Epub 2014 Dec 1. Erratum in: Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):E5764.

12.

Quantitative proteomics for cardiac biomarker discovery using isoproterenol-treated nonhuman primates.

Song B, Liu Y, Parman T, Liu S, Miller JK, Liu X, Tanga MJ, Mirsalis J.

J Proteome Res. 2014 Dec 5;13(12):5909-17. doi: 10.1021/pr500835w. Epub 2014 Nov 7.

13.

New candidate biomarkers in the female genital tract to evaluate microbicide toxicity.

Fields S, Song B, Rasoul B, Fong J, Works MG, Shew K, Yiu Y, Mirsalis J, D'Andrea A.

PLoS One. 2014 Oct 21;9(10):e110980. doi: 10.1371/journal.pone.0110980. eCollection 2014.

14.

Pharmacokinetics and dose-range finding toxicity of a novel anti-HIV active integrase inhibitor.

Nair V, Okello M, Mishra S, Mirsalis J, O'Loughlin K, Zhong Y.

Antiviral Res. 2014 Aug;108:25-9. doi: 10.1016/j.antiviral.2014.05.001. Epub 2014 May 10.

15.

Evaluation of Antitrypanosomal Dihydroquinolines for Hepatotoxicity, Mutagenicity, and Methemoglobin Formation In Vitro.

Werbovetz KA, Riccio ES, Furimsky A, Richard JV, He S, Iyer L, Mirsalis J.

Int J Toxicol. 2014 Jul;33(4):282-287. Epub 2014 May 12.

16.

Serum biomarkers reveal long-term cardiac injury in isoproterenol-treated African green monkeys.

Liu Y, Parman T, Schneider B, Song B, Galande AK, Anderson D, Mirsalis J.

J Proteome Res. 2013 Apr 5;12(4):1830-7. doi: 10.1021/pr3011809. Epub 2013 Mar 28.

17.

Lead optimization of antimalarial propafenone analogues.

Lowes D, Pradhan A, Iyer LV, Parman T, Gow J, Zhu F, Furimsky A, Lemoff A, Guiguemde WA, Sigal M, Clark JA, Wilson E, Tang L, Connelly MC, Derisi JL, Kyle DE, Mirsalis J, Guy RK.

J Med Chem. 2012 Jul 12;55(13):6087-93. doi: 10.1021/jm300286a. Epub 2012 Jun 29.

18.

Evaluation of arylimidamides DB1955 and DB1960 as candidates against visceral leishmaniasis and Chagas' disease: in vivo efficacy, acute toxicity, pharmacokinetics, and toxicology studies.

Zhu X, Liu Q, Yang S, Parman T, Green CE, Mirsalis JC, de Nazaré Correia Soeiro M, Mello de Souza E, da Silva CF, da Gama Jaen Batista D, Stephens CE, Banerjee M, Farahat AA, Munde M, Wilson WD, Boykin DW, Wang MZ, Werbovetz KA.

Antimicrob Agents Chemother. 2012 Jul;56(7):3690-9. doi: 10.1128/AAC.06404-11. Epub 2012 Apr 16.

19.

Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.

Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.

J Med Chem. 2012 May 10;55(9):4205-19. doi: 10.1021/jm201642z. Epub 2012 Apr 18.

20.

Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-hepatitis B virus dinucleoside phosphorothioate.

Coughlin JE, Pandey RK, Padmanabhan S, O'Loughlin KG, Marquis J, Green CE, Mirsalis JC, Iyer RP.

Drug Metab Dispos. 2012 May;40(5):970-81. doi: 10.1124/dmd.111.044446. Epub 2012 Feb 10.

21.

Biodistribution, toxicology, and radiation dosimetry of 5-HT1A-receptor agonist positron emission tomography ligand [11C]CUMI-101.

Kumar DJ, Bai B, Ng HH, Mirsalis JC, Erlandsson K, Milak MS, Majo VJ, Prabhakaran J, Mann JJ, Parsey RV.

Int J Toxicol. 2011 Dec;30(6):611-8. doi: 10.1177/1091581811419024. Epub 2011 Oct 12.

22.

Neurological assessments after treatment with the antimalarial β-arteether in neonatal and adult rats.

Erickson RI, Defensor EB, Fairchild DG, Mirsalis JC, Steinmetz KL.

Neurotoxicology. 2011 Aug;32(4):432-40. doi: 10.1016/j.neuro.2011.03.003. Epub 2011 Apr 6.

PMID:
21477617
23.

WITHDRAWN. Neurological assessments after treatment with the antimalarial β-arteether in neonatal and adult rats.

Erickson RI, Defensor EB, Fairchild DG, Mirsalis JC, Steinmetz KL.

Neurotoxicology. 2011 Aug;32(4):423-31. doi: 10.1016/j.neuro.2011.02.005. Epub 2011 Mar 2. Retraction in: Neurotoxicology. 2011 Dec;32(6):988.

PMID:
21376079
24.

Preclinical pharmacokinetic, toxicological and biomarker evaluation of SR16157, a novel dual-acting steroid sulfatase inhibitor and selective estrogen receptor modulator.

Rausch L, Green C, Steinmetz K, LeValley S, Catz P, Zaveri N, Schweikart K, Tomaszewski J, Mirsalis J.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1341-52. doi: 10.1007/s00280-010-1430-x. Epub 2010 Aug 25.

PMID:
20737149
25.

Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.

Ray S, Madrid PB, Catz P, LeValley SE, Furniss MJ, Rausch LL, Guy RK, DeRisi JL, Iyer LV, Green CE, Mirsalis JC.

J Med Chem. 2010 May 13;53(9):3685-95. doi: 10.1021/jm100057h.

26.

Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs.

Coughlin JE, Padmanabhan S, Zhang G, Kirk CJ, Govardhan CP, Korba BE, O'Loughlin K, Green CE, Mirsalis J, Morrey JD, Iyer RP.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1783-6. doi: 10.1016/j.bmcl.2010.01.010. Epub 2010 Jan 11.

27.

Increased CCL2 expression and macrophage/monocyte migration during microbicide-induced vaginal irritation.

Alt C, Harrison T, Dousman L, Fujita N, Shew K, Tran TT, Shayesteh S, Matsukawa A, Mirsalis J, D'Andrea A.

Curr HIV Res. 2009 Nov;7(6):639-49.

28.

Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys.

Huang YY, Ma KH, Tseng TW, Chou TK, Ng H, Mirsalis JC, Fu YK, Chu TC, Huang WS, Shiue CY.

Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):545-55. doi: 10.1007/s00259-009-1281-z. Epub 2009 Oct 10.

PMID:
19820930
29.

Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component.

O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, Bakke J, Mirsalis J, d'Andrea AL, Hume SD, Bratcher B, Saucedo CJ, McMahon JB, Pogue GP, Palmer KE.

Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6099-104. doi: 10.1073/pnas.0901506106. Epub 2009 Mar 30.

30.

Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates.

Dieterich C, Puey A, Lin S, Swezey R, Furimsky A, Fairchild D, Mirsalis JC, Ng HH.

Toxicol Sci. 2009 Jan;107(1):258-69. doi: 10.1093/toxsci/kfn203. Epub 2008 Oct 16. Erratum in: Toxicol Sci. 2009 Mar;108(1):222. Lyn, Sylvia [corrected to Lin, Sylvia ].

31.

Microarray evaluation of the Listeria monocytogenes infection and amoxicillin treatment in mice.

Dieterich C, Iglehart D, Riccio E, Mirsalis JC, Ng HH.

Int J Toxicol. 2008;27(3):265-72. doi: 10.1080/10915810802152111.

PMID:
18569167
32.

Evaluation of chemopreventive agents for genotoxic activity.

Doppalapudi RS, Riccio ES, Rausch LL, Shimon JA, Lee PS, Mortelmans KE, Kapetanovic IM, Crowell JA, Mirsalis JC.

Mutat Res. 2007 May 18;629(2):148-60. Epub 2007 Feb 25.

PMID:
17387038
33.

Preclinical acute toxicity studies and dosimetry estimates of the novel sigma-1 receptor radiotracer, [18F]SFE.

Waterhouse RN, Zhao J, Stabin MG, Ng H, Schindler-Horvat J, Chang RC, Mirsalis JC.

Mol Imaging Biol. 2006 Sep-Oct;8(5):284-91.

PMID:
16924428
34.

Gene expression profiling of mouse host response to Listeria monocytogenes infection.

Ng HH, Frantz CE, Rausch L, Fairchild DC, Shimon J, Riccio E, Smith S, Mirsalis JC.

Genomics. 2005 Dec;86(6):657-67. Epub 2005 Aug 15.

35.

Evaluation of mutant frequencies of chemically induced tumors and normal tissues in lambda/cII transgenic mice.

Mirsalis JC, Shimon JA, Johnson A, Fairchild D, Kanazawa N, Nguyen T, de Boer J, Glickman B, Winegar RA.

Environ Mol Mutagen. 2005;45(1):17-35.

PMID:
15605353
36.

Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.

Ramanathan-Girish S, Catz P, Creek MR, Wu B, Thomas D, Krogstad DJ, De D, Mirsalis JC, Green CE.

Int J Toxicol. 2004 May-Jun;23(3):179-89.

PMID:
15204721
37.

In vivo transgenic mutation assays.

Thybaud V, Dean S, Nohmi T, de Boer J, Douglas GR, Glickman BW, Gorelick NJ, Heddle JA, Heflich RH, Lambert I, Martus HJ, Mirsalis JC, Suzuki T, Yajima N.

Mutat Res. 2003 Oct 7;540(2):141-51.

PMID:
14550498
38.

Skin irritation, basal epithelial cell proliferation, and carcinogenicity evaluations of a representative specialty acrylate and methacrylate.

Van Miller JP, Garman RH, Hermansky SJ, Mirsalis JC, Frederick CB.

Regul Toxicol Pharmacol. 2003 Feb;37(1):54-65.

PMID:
12662909
39.

Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome.

Mirsalis JC, Schindler-Horvat J, Hill JR, Green CE, Mitoma C, Tomaszewski JE, Tyson CA, Donohue SJ.

Cancer Chemother Pharmacol. 2003 Mar;51(3):193-201. Epub 2003 Jan 18.

PMID:
12655436
40.

Genotoxicity and toxicity of the potential cancer-preventive agent polyphenon E.

Chang PY, Mirsalis J, Riccio ES, Bakke JP, Lee PS, Shimon J, Phillips S, Fairchild D, Hara Y, Crowell JA.

Environ Mol Mutagen. 2003;41(1):43-54.

PMID:
12552591
41.

Genotoxicity and carcinogenicity studies of soy isoflavones.

Misra RR, Hursting SD, Perkins SN, Sathyamoorthy N, Mirsalis JC, Riccio ES, Crowell JA.

Int J Toxicol. 2002 Jul-Aug;21(4):277-85.

PMID:
12171629
42.

Genetic toxicology testing of the antimalarial drugs chloroquine and a new analog, AQ-13.

Riccio ES, Lee PS, Winegar RA, Krogstad DJ, De D, Mirsalis JC.

Environ Mol Mutagen. 2001;38(1):69-79.

PMID:
11473390
43.

Professional toxicology societies: web based resources.

Kehrer JP, Mirsalis J.

Toxicology. 2001 Jan 12;157(1-2):67-76.

PMID:
11164975
44.

Pyridine does not induce unscheduled DNA synthesis (UDS) in hepatocytes of male B6C3F1 mice treated in vivo.

MacGregor JA, Hamilton CM, Kubicek JE, Mirsalis JC.

J Appl Toxicol. 2000 Sep-Oct;20(5):389-93.

PMID:
11139169
45.

Micronucleated erythrocyte frequency in peripheral blood of B6C3F(1) mice from short-term, prechronic, and chronic studies of the NTP carcinogenesis bioassay program.

Witt KL, Knapton A, Wehr CM, Hook GJ, Mirsalis J, Shelby MD, MacGregor JT.

Environ Mol Mutagen. 2000;36(3):163-94.

PMID:
11044899
46.

In vivo transgenic mutation assays.

Heddle JA, Dean S, Nohmi T, Boerrigter M, Casciano D, Douglas GR, Glickman BW, Gorelick NJ, Mirsalis JC, Martus HJ, Skopek TR, Thybaud V, Tindall KR, Yajima N.

Environ Mol Mutagen. 2000;35(3):253-9.

PMID:
10737959
47.

Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity.

Freund YR, Mirsalis JC, Fairchild DG, Brune J, Hokama LA, Schindler-Horvat J, Tomaszewski JE, Hodge JW, Schlom J, Kantor JA, Tyson CA, Donohue SJ.

Int J Cancer. 2000 Feb 15;85(4):508-17.

48.

Mutational spectrum of dimethylnitrosamine in the liver of 3- and 6-week-old lacI transgenic mice.

de Boer JG, Mirsalis JC, Glickman BW.

Environ Mol Mutagen. 1999;34(2-3):80-3.

PMID:
10529729
49.

Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance.

Mirsalis JC, Schindler-Horvat J, Hill JR, Tomaszewski JE, Donohue SJ, Tyson CA.

Cancer Chemother Pharmacol. 1999;44(5):395-402.

PMID:
10501913
50.

Transgenic mouse mutation assay systems can play an important role in regulatory mutagenicity testing in vivo for the detection of site-of-contact mutagens.

Dean SW, Brooks TM, Burlinson B, Mirsalis J, Myhr B, Recio L, Thybaud V.

Mutagenesis. 1999 Jan;14(1):141-51. Review.

PMID:
10474836

Supplemental Content

Loading ...
Support Center